pain and form the basis for communication among healthcare providers, such as General Practitioners, in order to improve appropriate prescribing policies.

No conflict of interest.

**DGI-048** NEW ORAL ANTICOAGULANTS: HOW ARE THEY BEING USED?

doi:10.1136/ejhpharm-2013-000276.314

V Saavedra Quirino, C Folguera Olias, A Torralba Amanz. Hospital Universitario Puerta de Hierro, Pharmacy, Madrid, Spain

**Background** The expectations raised by the new oral anticoagulants (OACs) have led some experts to view them as the ideal substitute for anti-vitamin K.

**Purpose** To analyse the use of dabigatran and rivaroxaban in a Spanish tertiary hospital since their inclusion in the formulary to date.

**Materials and Methods** The period of study was January 2010–September 2012. We carried out a study on the patients prescribed either of the two new OACs included in the formulary. A data collection sheet was designed in which the parameters recorded were: gender, age, indication and observations (if any adverse reaction had been described).

**Results** In the period January 2010–September 2012, a total of 86 patients (38% male) were treated with rivaroxaban, with a mean age of 66 (21–91) years; whereas in the period December 2011–September 2012 (dabigatran was included later in the formulary), 55 patients (60% male), with a mean age of 74 (45–95) years, were treated with dabigatran. 84 out of the 86 patients treated with rivaroxaban received it in prophylaxis after having undergone knee or hip replacement. Nevertheless, dabigatran was used mostly in non-surgery patients, only 2 out of the 55 patients were traumatology patients.

Only one minor bleed was reported in one patient diagnosed with atrial fibrillation and treated with dabigatran, and it should be taken into account that this patient exhibited thrombocytopenia at the time the bleeding occurred. No other adverse effects related to the administration of these drugs were found.

To date, the price of these new OACs is more than ten times higher than anti-vitamin K.

**Conclusions** Despite the fact that the new OACs have been shown as a good option compared to anti-vitamin K, their use in our hospital is still moderate, for two main reasons: their high cost and the uncertainty about their management in critical situations.

No conflict of interest.

**DGI-049** OCTEOTRIDE IN GASTROINTESTINAL ANGIODYSPLASIA

doi:10.1136/ejhpharm-2013-000276.315

GJ Narcos, I González, F Gutierrez, C Valcúrcel, I Rodríguez, M Pérez, T Virgós, M Bullejos, M Chafer. Hospital Universitario de Canarias, Pharmacy, La Laguna, Spain

**Background** Gastrointestinal angiodysplasia (GIAD) may either be asymptomatic or induce overt or occult bleeding with a high risk of recurrence. Numerous therapeutic options are available but an evidence basis is lacking.

**Purpose** To analyse costs and improve the clinical parameters in patients with GIAD after intramuscular administration of long-acting octreotide (Oc-LAR) 10 mg/month.

**Materials and Methods** Retrospective observational study from January to December 2011. We reviewed the medical records of patients who were prescribed long-acting Octreotide for GIAD. Clinical data (haemoglobin, vials of iron needed, blood transfusions) and demographic characteristics of the patients were tabulated using Excel. We compared clinical results pre- and post-Oc-LAR use. The x² test was used for category variables, and the t-test was used for continuous variables with normal distribution using SPSS statistical software. Clinical and monetary value were derived from publicly available data. The study perspective was from the hospital management point of view.

**Results** 17 patients were included in the study. 11 were men and 6 women. The mean age was 75.2 years. The direct costs were €350 per red blood cell transfusion, €167 per iron administration and €694.95 for Oc-LAR.

The mean Hb levels were 9.0 g/dl and 9.6 g/dl (p < 0.0001) before and after treatment. Blood transfusions decreased from 1.8 to 1.7 (P = 0.258). However iron requirements were higher after treatment started. 2.5 vials of iron, up from 1.9 (P = 0.027). And there was an increase in hospital admissions annually 3.3 vs. 2.3 before treatment (P = 0.311). So Oc-LAR use increased the average annual cost per patient by 8,401.6€ without stopping disease progression.

**Conclusions** Pharmacological treatments are typically considered in refractory cases of endoscopic failure and recurrent bleeding. Oc-LAR seems to be more suitable in terms of efficacy and tolerance according to the bibliography. However, our study shows that Octreotide long-acting formulation treatment was not cost effective and failed to stop the natural evolution of the disease.

No conflict of interest.

**DGI-050** OFF-LABEL USES OF MYCOPHENOLATE MOFETIL

doi:10.1136/ejhpharm-2013-000276.316

MC Izquierdo Navarro, V Martinez Santana, C Matalanna Martin, MT Sánchez Sánchez. Hospital Clínico Universitario, Pharmacy Department, Valladolid, Spain

**Background** The implementing Law 1015/2009 normalises the compassionate use of investigational drugs, access to off-label and unauthorised drugs in Spain.

Mycophenolate mofetil/Mycophenolic Acid (MM/MA) have been used in off-label conditions to treat kidney diseases.1–5

**Purpose** To describe the dose and effectiveness of MM/MA in the treatment of nephritis.

**Materials and Methods** Observational, cross-sectional study including all patients diagnosed with nephritis treated with MM/MA in off-label conditions during July 2012.

Diagnosis and dose were recorded. Serum creatinine and the value of urinary proteins were collected at the beginning of the study. The urinary proteins value decreased from 35.4 mg/dl (SD 24.6) at the beginning of the study to 28.6 mg/dl (SD 21.4) at the end of the study.

The mean serum creatinine at the beginning of treatment was 1.6 mg/dl (SD 0.9) and decreased to 1.4 mg/dl (SD 0.6) at the end of the study. The urinary proteins value decreased from 35.4 mg/dl (SD 24.6) at the beginning of treatment to 28.6 mg/dl (SD 21.4) at the end of the study.

**Results** 22 patients were included, 14 were treated with MA and 8 with MM.

Of the patients treated with MA, 50% asked to be treated for nephritis, 28.6% for lupus and 21.4% for polyarteritis nodosa. (Both the lupus and the polyarteritis nodosa were giving clinical kidney symptoms.)

The usual dosage was every 12 hours (12/14), the most used dose being 560 mg (10/14).

The mean serum creatinine at the beginning of treatment was 1.14 mg/dl (SD 0.4) and decreased to 0.95 mg/dl (SD 0.3) at the end of the study. The urinary proteins value decreased from 35.4 mg/dl (SD 7.3) at the beginning of treatment to 26.2 mg/dl (SD 3.2) at the end of the study.

Of the patients treated with MM 62.5% requested treatment of nephritis and 37.5% of lupus. (The usual dosage was every 12 hours (7/8), the most used dose being 500 mg (3/6), 400 mg (2/8), 1500 mg, 1000 mg and 250 mg (1/8).

The mean serum creatinine at the beginning of treatment was 1.35 mg/dl (SD 0.6) and decreased to 1.13 mg/dl (SD 0.5) at the end of the study. The urinary proteins value decreased from 30.11 mg/dl (SD 24.6) at the beginning of the study to 28.6 mg/dl (SD 21.4) at the end of the study.